Brolucizumab-impurities | Pharmaffiliates

Brolucizumab

Brolucizumab-dbll injection is used to treat neovascular (wet) age-related macular degeneration (AMD). Reference standards of Brolucizumab API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Brolucizumab - API Standards 
    [catalogue_number] => PA 02 2500000
    [category_ids] => ,78,70,82,76,
    [chemical_name] => 
    [weight] => NA
    [form] => NA
    [cas] => 1531589-13-5
    [pslug] => 1531589-13-5-brolucizumab-api-pa022500000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 02 2500000

Brolucizumab - API Standards


  • Catalogue No.:PA 02 2500000

  • CAS :

    1531589-13-5

  • Molecular Formula : NA

  • Molecular Weight : NA